Compare Elastic NV (ESTC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elastic NV vs State Street SPDR S&P Biotech ETF — how do they compare? Elastic NV trades at $76.41 (market cap $7.94B), while State Street SPDR S&P Biotech ETF trades at $159.24. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Elastic NV nearer its low. Which is the better fit depends on your goals.
| ESTC | XBI | |
|---|---|---|
Market Cap | $7.94B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $94.47 | $164.28 |
52-Week Low | $43.30 | $86.92 |
Enterprise Value | $7.16B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Elastic (ESTC) trades at $75.88, down 0.58% on the day, with a bullish technical outlook supported by moving averages and strong institutional interest. Recent earnings beats and a projected net profit margin of 21.14% for 2026 highlight improving fundamentals, while collaborations with OpenAI and AWS security distinctions underscore strategic growth. The stock faces headwinds from high valuation multiples and a negative net income in 2025.
The outlook remains positive given analyst consensus and product innovations, but risks include elevated P/E and EV/EBITDA ratios, potential legal scrutiny, and competitive pressures. Upside is supported by a $106 high price target, though investor caution is warranted near-term due to overbought RSI levels.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
